IMPACT Therapeutics, Inc., a Nanjing-based biotech founded in 2009 and specializing in synthetic lethality, has filed for an IPO on the Hong Kong Stock Exchange. The company’s lead product, Senaparib (a PARP1/2 inhibitor), was approved in China in January 2025 for first-line maintenance treatment of ovarian cancer in all patients regardless of BRCA status. Its pipeline includes 13 assets: 1 commercialized, 4 in clinical stages, and 7 preclinical candidates targeting key synthetic lethality pathways such as PARP1-selective, ATR, WEE1, PKMYT1, DHX9, ATM, USP1, CHK1/2, PROTACs, and CEACAM5 ADCs. Despite generating RMB 38.3M in 2025 revenue—more than half from drug sales—the company reported a net loss of RMB 295.9M and carries a RMB 980.2M redemption liability that would convert to equity upon successful IPO completion. Key investors include Tencent, WuXi AppTec, LAV, and Decheng Capital.

As an investigational human monoclonal antibody targeting CD38, felzartamab possesses significant clinical potential due to its unique mechanism of action. It selectively depletes CD38-positive plasma cells, blocking the generation of pathogenic antibodies at the source.

On April 14, 2026, Sierra Medical's independently developed SIERRA VISION SYSTEM® Ophthalmic Anterior and Posterior Segment Surgical Platform received the NMPA Class III medical device registration certificate. As the first domestically produced ophthalmic anterior and posterior segment integrated surgical platform in China to feature a high level of integration for core functions such as phacoemulsification, vitrectomy, and laser, it can cover the entire surgical process for both anterior and posterior segments without additional equipment, providing a "one-stop" solution. The approval of this platform marks a significant upgrade in China’s high-end ophthalmic surgical equipment, filling the gap in the domestic market for integrated phaco-vitrectomy machines and advancing Chinese ophthalmic devices into a new phase of high-end, platform-based development. With the intensification of global aging and an increase in retinal diseases, phaco-vitrectomy machines have become essential equipment for minimally invasive precision treatment of eye conditions; however, the market has long been dominated by overseas manufacturers. Imported devices are costly and face challenges in supply chain stability, leading to strong clinical demand for domestic alternatives. However, previous solutions from some domestic brands were not without flaws.

Vaccines are not ordinary commodities. As a vital component of public health systems, they are subject to stringent regulation, making export exceptionally challenging. How have Chinese domestic vaccine manufacturers overcome these obstacles to open up key markets overseas?

IMPACT Therapeutics, Inc., a Nanjing-based biotech founded in 2009 and specializing in synthetic lethality, has filed for an IPO on the Hong Kong Stock Exchange. The company’s lead product, Senaparib (a PARP1/2 inhibitor), was approved in China in January 2025 for first-line maintenance treatment of ovarian cancer in all patients regardless of BRCA status. Its pipeline includes 13 assets: 1 commercialized, 4 in clinical stages, and 7 preclinical candidates targeting key synthetic lethality pathways such as PARP1-selective, ATR, WEE1, PKMYT1, DHX9, ATM, USP1, CHK1/2, PROTACs, and CEACAM5 ADCs. Despite generating RMB 38.3M in 2025 revenue—more than half from drug sales—the company reported a net loss of RMB 295.9M and carries a RMB 980.2M redemption liability that would convert to equity upon successful IPO completion. Key investors include Tencent, WuXi AppTec, LAV, and Decheng Capital.

Weimai Inc., an AI-driven healthcare digital platform, has filed its prospectus for a Hong Kong IPO. The company reported FY2025 revenue of RMB 863.4 million, up 32.3% YoY, driven by rapid growth in CareAI/AI Services (+44.6%) and the launch of a high-margin Dedicated IP Licensing segment (32.8% gross margin). Despite achieving positive Adjusted EBITDA of RMB 1.4 million for the first time, Weimai posted a net loss of RMB 290.1 million, largely due to soaring share-based compensation expenses (RMB 237.8 million). With 188 CareAI deployments and 4,800 API integrations, the company holds ~4% market share in China’s fast-growing AI healthcare sector, which is projected to expand at a 32.7% CAGR through 2030.

Weimai Inc., an AI-driven healthcare digital solutions platform, has filed for a Hong Kong Stock Exchange listing. The company reported FY2025 revenue of RMB 863.4M, up 32.3% YoY, with gross margin improving to 21.7%. Despite a net loss of RMB 290.1M—widened primarily due to RMB 237.8M in non-cash charges—its adjusted EBITDA turned positive at RMB 1.4M. Weimai operates a B2B2C ecosystem featuring CareAI (188 hospital deployments), Medical AI Solutions (M.A.S), an API ecosystem (4,800 integrations), and proprietary IP licensing (70 assets). It holds a 5.2% market share in China’s CareAI segment within a rapidly growing AI healthcare market projected to expand at a 32.7% CAGR through 2030. However, R&D spending remains below peer averages at 8.3% of revenue, raising questions about the sustainability of its AI differentiation.

As an investigational human monoclonal antibody targeting CD38, felzartamab possesses significant clinical potential due to its unique mechanism of action. It selectively depletes CD38-positive plasma cells, blocking the generation of pathogenic antibodies at the source.

Preliminary statistics from VCBeat tracked 10 financing events in China's healthcare sector between April 13 and 17, 2026 (excluding IPOs and private placements). The period was led by Polyncure's Seed Round in the tens of millions of RMB, followed by Fusu Life Science and Technology's Angel Round of RMB 20 million.

METiS TechBio Co., Ltd., a pre-commercial AI-driven nanomedicine company founded in 2020, has filed for an IPO on the Hong Kong Stock Exchange under Chapter 18C. The company leverages its NanoForge platform—powered by a proprietary lipid library of over 10 million structures—and four core AI platforms (AiTEM, AiLNP, AiRNA, and NanoForge) to accelerate drug delivery innovation. Its lead program, MTS-004, entered Phase III trials following a RMB 100 million out-licensing deal in September 2025, driving 2025 revenue to RMB 105 million from just RMB 1.5 million in 2024. Despite narrowing net losses to RMB 391.8 million in 2025 and holding RMB 828.3 million in cash, METiS reports accumulated losses of RMB 1.75 billion and high customer concentration risk. The IPO proceeds will support AI platform enhancement, clinical advancement of MTS-201/105/109, non-hepatic LNP validation, global partnerships, and animal health initiatives.

However, these synergistic integration efforts have not reached the ideal state. Trividia and PTS have often experienced performance losses and goodwill impairment, affecting Sinocare's profits. For example, in 2019, the business operations of PTS were impacted, resulting in goodwill impairment of 25 to 50 million RMB; Trividia's operating loss impacted Sinocare's investment income by approximately -60 to -75 million RMB. In 2020, both PTS and Trividia were in a state of operating loss. In 2021, Trividia continued to incur losses; in 2023, Trividia faced operating losses and goodwill impairment.

On April 16, 2026, 15 days after Eli Lilly's Orforglipron (brand name Foundayo) received FDA approval for obesity indications, the results of the ACHIEVE-4 trial were announced. In a population with type 2 diabetes combined with overweight/obesity and elevated cardiovascular risk, Foundayo showed a 16% reduction in MACE-4 risk compared to insulin glargine, achieving non-inferiority, and a 57% reduction in all-cause mortality risk, becoming the only secondary endpoint to reach statistical significance. Amidst the GLP-1赛道 being dominated by Novo Nordisk's injectables, Eli Lilly opted to develop small-molecule oral formulations. Orforglipron is a de novo designed non-peptide small molecule, around which a global Phase III project matrix has been constructed. By 2026, it has become the oral metabolic drug closest to commercialization in Eli Lilly’s pipeline. Eli Lilly defined ACHIEVE-4 as "the largest and longest Foundayo study for type 2 diabetes to date," reflecting its high emphasis on cardiovascular data.

In the past, the industry focused more on whether ADCs had sufficient killing power and whether they could deliver the payload to tumor cells. However, in recent years, it has become increasingly clear that what determines a project's ability to be sustainably advanced is not only "whether it hits the target accurately" but also "whether it can control off-target toxicity, systemic exposure, and normal tissue damage within a reasonable range while hitting the target accurately." Especially during the clinical advancement of some projects, issues such as premature payload release, off-target exposure, and a less-than-ideal therapeutic window often affect dose design, indication expansion, and even the subsequent development potential of the project.

Beijing has introduced the "32 Measures" for three consecutive years to support the development of innovative pharmaceuticals. The Beijing Drug Administration has established a service mechanism called "Project-based Management for Innovative Drugs and Medical Devices," focusing on "early intervention, tailored strategies for each product, full-process guidance, and synchronized research and review." Since its launch in 2024, the initiative has been continuously expanding and improving, aiming to include no fewer than 400 innovative products by 2026, providing comprehensive exclusive service guarantees. The race for drug and device innovation is a race against time. Under the project-based management system, Beijing is expected to approve six innovative drugs and ten Class III innovative medical devices in 2025, setting the highest annual record during the "14th Five-Year Plan" period, with Class II innovative medical devices increasing by 50% year-on-year. To date, Beijing leads the country in the number of approved innovative medical devices and has facilitated the approval of 29 imported drugs and devices over the past three years, ranking among the top in China for rare disease medications. Since 2026, Beijing has also driven the approval and market launch of multiple innovative drugs and medical devices. Project-based management integrates resources from various parties, benefiting innovation research, enterprise growth, and patients.

3M Corp. Achieves Better-than-Expected Performance in Fiscal Year 2025 After Spinning Off Healthcare Business into Independently Listed Solventum

On the occasion of World Cancer Day and Cancer Prevention and Control Awareness Week 2026, VCBeat launched a special feature. China's cancer prevention and treatment is currently at a critical stage of full-chain transformation, with advanced therapies continuously breaking through. However, clinical needs remain unmet due to a shortage of medical resources and drugs. The industry is focusing on popular targets, but the root cause lies in insufficient understanding of diseases. There are approximately 3,000 targets with true drug development potential, yet only about 100 have been covered by FDA approvals. Zhao Yu, researcher at the Western Institute of Computing Technology and deputy director of the Turing-Darwin Laboratory, believes that human understanding of diseases relies on sporadic inspiration, which is slow, inefficient, and uncontrollable, failing to keep up with clinical demands. Today, AI may revolutionize the logic of innovative drug research and development, acting as an "in vitro brain with an IQ of 1000" for humanity. By building computational medicine platforms based on information theory, it can mine intrinsic connections within massive high-dimensional data, develop "emergent" capabilities, reach underlying mechanisms, and foster different AI-driven pharmaceutical pathways, moving from "finding molecules" toward "understanding life."

The drug pricing rules, which focus on clinical value and normalize fully transparent prices across all channels, are being further refined. Among these, high-level innovative drugs with a high degree of innovation and significant clinical value will be supported in setting prices that align with their high investment and high risk during the initial market entry period, maintaining relatively stable prices for a certain period.

On April 14, Novo Nordisk announced a strategic partnership with OpenAI to fully deploy AI technology across all aspects from drug discovery to commercial operations. On March 20, the core compound patent of semaglutide expired in China, and applications for the market approval of domestically produced generic drugs have entered the review process in large numbers. On April 1, Eli Lilly announced that its oral small-molecule GLP-1 receptor agonist had been approved for marketing, creating competitive pressure on Novo Nordisk. With the loosening of patent protection and intensifying competition, the urgency to find "the next semaglutide" has increased, and Novo Nordisk needs a new paradigm for drug discovery. According to the joint statement, the core objective of this collaboration is to use AI tools to analyze complex datasets, identify new drug candidates, and shorten the time from research to clinical application, while improving the efficiency of production, supply chain, and commercial operations. The decision to partner with OpenAI is based on the logic of maximizing the value of proprietary data and addressing systemic efficiency challenges.

For a long time, Biotech has been regarded as a synonym for high investment and slow returns. However, Everest Medicines has officially entered the value realization phase through the dual drivers of "licensing collaboration + self-research." The acquisition of Hasten Singapore by Everest Medicines is not simply about licensing deal or expansion; rather, it serves as a validation of the commercial platform's capacity spillover and regional replication capabilities.

But in practice, patients often feel that there are no effective drugs available. The progression of the disease and the ineffectiveness of the drugs tend to exceed expectations, while the complexity and side effects of upgraded drugs increase sharply, with unsatisfactory efficacy. About half of the patients find that standard-dose second-generation antihistamines are directly ineffective. Of these, nearly half also find no effect after increasing the dose or combining antihistamines for a year, and more than 40% of patients still have not achieved effective control after one year.

However, these synergistic integration efforts have not reached the ideal state. Trividia and PTS have often experienced performance losses and goodwill impairment, affecting Sinocare's profits. For example, in 2019, the business operations of PTS were impacted, resulting in goodwill impairment of 25 to 50 million RMB; Trividia's operating loss impacted Sinocare's investment income by approximately -60 to -75 million RMB. In 2020, both PTS and Trividia were in a state of operating loss. In 2021, Trividia continued to incur losses; in 2023, Trividia faced operating losses and goodwill impairment.

Multinational pharmaceutical companies are now capturing high ground in the radiopharmaceutical space through a dual strategy of deep collaboration plus capacity pre-positioning — securing both cutting-edge technologies and project pipelines while also establishing localized production of scarce radionuclides ahead of time. The global radiopharmaceutical competition has formally entered a stage of value-chain positioning battles.

3M Corp. Achieves Better-than-Expected Performance in Fiscal Year 2025 After Spinning Off Healthcare Business into Independently Listed Solventum

United Imaging has showcased more imaging information from uCT Ultima at its booth this year, combined with unique rendering technology, which indeed elevates imaging and performance to a new level. In terms of commercialization, uCT Ultima has been installed and officially put into clinical use at West China Xiamen Hospital, Sichuan University, and Huaxi Xiamen Hospital. Regarding clinical validation, the on-site staff stated that more than 4,000 clinical scans have been completed in total.

Gilead Sciences, Not Content as HIV Leader, Shows Strong Ambition in Oncology. On April 9, it secured global development rights for KT-200. The original developer, Kymera, will receive a $45 million milestone payment and is eligible for substantial total payments and tiered royalties. On the 100th day of 2026, Gilead made its fourth move, with a potential total deal value of approximately $15.725 billion, including the acquisition of CAR-T company Arcellx, the merger with Ouro Medicines, and the purchase of Germany's next-generation ADC company Tubulis Technologies. KT-200, the subject of this transaction, is the world’s first oral molecular glue degrader targeting CDK2, which selectively eliminates CDK2, a key driver of tumor growth, offering a more precise, safe, and effective oral treatment option for cancers dependent on CDK2 activity. Preclinical tests have shown strong activity, potential for brain penetration, and good safety.

In 2018, CMS announced that it would no longer engage in agency business in the future, but instead transition to a model of co-development profit-sharing or direct acquisition of drug assets, aiming to transform into an innovative pharmaceutical company. It also announced its transformation goal: to bring 10 significant innovative drugs to market in China in the future.

It should be noted that in invasive artificial hearts, higher flow support is not always better. Instead, multiple dimensions such as product size, support duration, and perfusion sealing technology need to be considered to provide tailored solutions for corresponding patients. For instance, the Impella series includes several models such as Impella CP, Impella 5.0, and Impella 2.5, offering different levels of maximum flow support at 3.7L/min, 5L/min, and 2.5L/min respectively, to meet the needs of different patients.

An unavoidable issue is that the clinical application of pan-KRAS inhibitors still faces inherent technical challenges. For example, achieving high selectivity for mutant KRAS over wild-type KRAS and other RAS subtypes to minimize off-tumor toxicity remains difficult. Additionally, the short half-life of existing pan-KRAS inhibitors and the unclear mechanisms of resistance also limit their widespread clinical use to some extent.

Pursuant to the merger agreement, as a shareholder of Ouro Medicines, Keymed Biosciences will receive approximately $250 million in upfront payment upon completion of the transaction, along with milestone payments of up to approximately $70 million, resulting in total consideration of approximately $320 million. Concurrently, the tiered sales royalties for CM336/OM336 will be fulfilled by Gilead.

Recently, Hengrui Pharma announced that the New Drug Application (NDA) for its independently developed Shudi Insulin Noiiglutide Injection (HR17031) has been formally accepted by the National Medical Products Administration (NMPA). However, the acceptance of this product appears to signal the beginning of a defensive battle rather than a charge forward.